Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lumixa is a professional phototherapy system that utilizes Fluorescent Light Energy (FLE) to treat various skin conditions and signs of aging. It consists of a topical, non-absorbing gel containing patented exogenous chromophores (such as Fluorophyll N, Fluorocumin C, and Fluorospir) that act as photoconverters. When applied to the skin and activated by a specific LED light source, these chromophores absorb photons and re-emit a dynamic spectrum of hyperpulsed, polychromatic fluorescent light across multiple wavelengths. This energy penetrates the epidermal and dermal layers to induce photobiomodulation, which stimulates mitochondrial activity, increases ATP production, and modulates cellular signaling in fibroblasts and keratinocytes. Lumixa is primarily used to address 'inflammageing', reduce fine lines and wrinkles, and stimulate collagen production without causing thermal damage or downtime.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lumixa.